Last reviewed · How we verify
VV116
At a glance
| Generic name | VV116 |
|---|---|
| Sponsor | Vigonvita Life Sciences |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of Deuremidevir Hydrobromide for Suspension in Chinese Infants Hospitalized With RSV (PHASE2)
- A Study to Evaluate the Bioavailability, Food Effect and Pharmacokinetics of Deuremidevir Hydrobromide for Suspension (PHASE1)
- A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral Deuremidevir Hydrobromide for Suspension (PHASE1)
- JT001 (VV116) for the Early Treatment of COVID-19 (PHASE2, PHASE3)
- JT001 (VV116) for the Treatment of COVID-19 (PHASE3)
- Evaluate the Pharmacokinetics, Safety and Tolerability of JT001 Tablets (PHASE1)
- Efficacy and Safety of JT001 (VV116) Compared With Favipiravir (PHASE3)
- Efficacy and Safety of JT001 (VV116) Compared With Paxlovid (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VV116 CI brief — competitive landscape report
- VV116 updates RSS · CI watch RSS
- Vigonvita Life Sciences portfolio CI